

1 **Antigenic determinants of SARS-CoV-2-specific CD4⁺ T cell lines reveals M protein-driven**
2 **dysregulation of interferon signaling**

3

4 Pedro Henrique Gazzinelli-Guimaraes^{1*}; Gayatri Sanku^{1*}; Alessandro Sette²; Daniela
5 Weiskopf²; Paul Schaughency³; Justin Lack³; Thomas B. Nutman^{1#}

6

7 ¹Laboratory of Parasitic Diseases, NIAID, National Institutes of Health, USA

8 ²Center for Infectious Disease, La Jolla Institute for Immunology, USA

9 ³Frederick National Laboratory for Cancer Research, National Institutes of Health, USA

10

11 * These authors contributed equally to this paper

12 #Corresponding author: Thomas B. Nutman, 4 Center Dr. Room 211, National Institutes of
13 Health, Bethesda, MD, 20892-0425, Tel: 301-496-5399, e-mail: tnutman@niaid.nih.gov

14

15 **Abstract**

16 We generated CD4⁺ T cell lines (TCLs) reactive to either SARSCoV-2 spike (S) or
17 membrane (M) proteins from unexposed naïve T cells from six healthy donor volunteers to
18 understand in fine detail whether the S and M structural proteins have intrinsic differences in
19 driving antigen-specific CD4⁺ T cell responses. Having shown that each of the TCLs were
20 antigen-specific and antigen-reactive, single cell mRNA analyses demonstrated that SARS-CoV-
21 2 S and M proteins drive strikingly distinct molecular signatures. Whereas the S-specific
22 responses are virtually indistinguishable from those responses induced by other viral antigens
23 (e.g. CMV), the M protein-specific CD4⁺ TCLs have a transcriptomic signature that indicate a
24 marked suppression of interferon signaling, characterized by a downregulation of the genes
25 encoding ISG15, IFITM1, IFI6, MX1, STAT1, OAS1, IFI35, IFIT3 and IRF7 (a molecular
26 signature which is not dissimilar to that found in severe COVID-19). Our study suggests a
27 potential link between the antigen specificity of the SARS-CoV-2-reactive CD4⁺ T cells and the
28 development of specific sets of adaptive immune responses. Moreover, the balance between T
29 cells of significantly different specificities may be the key to understand how CD4⁺ T cell
30 dysregulation can determine the clinical outcomes of COVID-19.

31

32 **Introduction**

33 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the novel viral agent of
34 the coronavirus disease 2019 (COVID-19) has resulted in widespread global morbidity and
35 mortality [1]. Infection with SARS-CoV-2 is characterized by a broad spectrum of clinical
36 syndromes, which may range from asymptomatic infection to mild symptoms to severe
37 pneumonia and acute respiratory distress syndrome [2, 3]. According with the World Health
38 Organization weekly epidemiological updates on COVID-19 (Edition 70), the current cumulative
39 number of cases and deaths reported globally is almost 270 million and over 5.3 million
40 respectively.

41 Immunological and clinical studies of acute and convalescent COVID-19 patients have
42 observed that SARS-CoV-2-specific antibodies and T cell responses are strongly associated with
43 milder disease and accelerated viral clearance [4-6] . Indeed, SARS-CoV-2-specific CD4⁺ and
44 CD8⁺ T cell responses have been reported as crucial for the control and resolution of primary
45 SARS-CoV-2 infection [7]. Varying approaches have been taken to quantify and characterize
46 virus-specific T cell responses in acute, convalescent, and severe patients, in a quest to
47 understand the nature of antigen specificity and function of the adaptive response to SARS-CoV-
48 2 [3, 6, 8, 9]. The response to the structural proteins, including spike (S), nucleocapsid (N),
49 membrane (M), and non-structural proteins (nsp3, nsp4, ORF3a, and ORF8), has been the main
50 targets for study. Using HLA predicted peptide megapools (MP) of the SARS-CoV-2 proteome,
51 Grifoni et al. [10] demonstrated that SARS-CoV-2-specific CD4⁺ T cell responses were found in
52 100% of patients convalescing from COVID-19, with the majority of the CD4⁺ T cell reactivity
53 directed to SARS-CoV-2 spike, M, and N proteins. On average, these antigens accounted for
54 27%, 21%, and 11% of the total CD4⁺ T cell response, respectively.

55 The CD4⁺ T cell responses to the SARS-CoV-2 S or N proteins have been shown to
56 correlate with the magnitude of the anti-SARS-CoV-2 neutralizing antibodies in recovered
57 patients [8, 10] , a finding suggesting a potential role for the S protein in triggering a protective
58 response to COVID-19. The SARS-CoV-2 M protein, in contrast, has been implicated in driving
59 evasion of protective immune responses, a process felt to occur by the manipulation of innate
60 antiviral immune responses ,most specifically by interfering with interferon (IFN) signaling
61 pathways and by antagonizing the production of type I and III IFN production [11-14] . This M-
62 driven antiviral immune suppression appears to favor SARS CoV-2 viral replication.

63 To understand in fine detail the molecular nature of the virus-specific CD4⁺ T cell
64 response to the SARS CoV-2 structural proteins, here, we generated (in a non-biased manner) 12
65 human CD4⁺ T cell lines (TCLs) reactive to either S protein or M protein from naïve T cells
66 obtained well prior to the COVID19 pandemic from 6 healthy donors with the aim of comparing
67 their molecular properties and function. Our data suggest that SARS-CoV-2 S and M proteins
68 each drive a strikingly distinct molecular signature in TCLs driven under neutral conditions.
69 Whereas the S-specific responses are virtually indistinguishable from those responses induced by
70 other viruses (e.g. CMV), the M protein-specific CD4⁺ TCLs have a transcriptomic signature that
71 demonstrates marked suppression of STAT1-IFNs-interferon pathway signaling, a signature
72 that is virtually indistinguishable from the molecular signature seen associated with severe
73 COVID-19.

74

75

76

77

78 **Results**

79 **Specificity and reactivity of CD4⁺ TCLs to SARS-CoV-2 spike and membrane proteins**

80 Purified naïve (CD45RA⁺CD45RO⁻) CD4⁺ T cells from the PBMCs of 6 healthy
81 (unexposed to SARS-CoV-2) donor volunteers, obtained prior to 2019, were differentiated *in*
82 *vitro* into SARS-CoV-2-specific CD4⁺ TCLs by rounds of stimulation and expansion using
83 autologous dendritic cells loaded with peptide megapools (MP) covering either the entire
84 sequence of SARS-CoV-2 spike protein (MP-S), or covering the complete sequence of SARS-
85 CoV-2 membrane protein (MP-M) (Figure 1A). After three rounds of *in vitro* antigenic
86 stimulation with either S- or M- specific MP in the presence of IL-2 and feeder cells, the CD4⁺
87 TCLs were assessed. Following *in vitro* stimulation, the generation of the SARS-CoV-2-reactive
88 CD4⁺ T cells to MP-S or MP-M were identified based on the expression of CD154 and CD69.
89 Figure 1B illustrates a representative analysis showing that 44.6% of MP-S-specific CD4⁺ TCL
90 were CD69⁺CD154⁺ in comparison to only 0.87% with their respective naïve CD4⁺ T cells.
91 Similarly, 51.7% of the MP-M-specific CD4⁺ TCL were CD69⁺ and CD154⁺ when compared
92 with 0.59% of their respective naïve CD4⁺ T cells. Moreover, upon stimulation with their
93 respective MP, the vast majority of CD69⁺CD154⁺ MP-S specific- and MP-M specific-CD4⁺ T
94 cell lines were either IFN- γ ⁺ or TNF- α ⁺ (Figure 1B).

95 We next characterized each of SARS-CoV-2-specific CD4⁺ TCLs for antigen specificity
96 and reactivity (Figure 2). All 6 MP-S specific- (Figure 2A) and MP-M specific-CD4⁺ TCLs
97 (Figure 2B) were cultured *in vitro* in the absence or in the presence of the respective MP or in
98 the presence of a peptide megapool covering the entire sequence of the non-related
99 cytomegalovirus (CMV). PMA/ionomycin was also used as the positive control for the assay.
100 When MP-S-specific CD4⁺ TCLs were stimulated with MP-S, it was observed a significant

101 increase in the frequency in each of the 6 individual CD4⁺ TCLs expressing CD69⁺CD154⁺ and
102 producing either IFN- γ ⁺ or TNF- α ⁺ when compared with non-stimulated cells ($24.9 \pm 9.5\%$ vs
103 $5.9 \pm 2.3\%$, $p=0.015$). This activation failed to occur when the TCLs were stimulated with MP-
104 CMV ($8.0 \pm 1.9\%$ vs $5.9 \pm 2.3\%$, $p=0.360$). Likewise, the stimulation of MP-M-specific CD4⁺
105 TCLs with MP-M, also induced a marked increase in the frequency in each of the 6 CD4⁺ TCLs
106 expressing CD69⁺CD154⁺ and producing either IFN- γ ⁺ or TNF- α ⁺ when compared with non-
107 stimulated cells ($25.4 \pm 18.3\%$ vs $4.3 \pm 2.4\%$, $p=0.031$). There was little to no reactivity to MP-
108 CMV stimulation ($3.3 \pm 1.7\%$ vs $4.3 \pm 2.4\%$, $p=0.360$) when compared with the media control.

109

110 **CD4⁺ TCLs reactive to S and M proteins reveals distinct transcriptomic signature**

111 Having confirmed the specificity and reactivity of each MP-S- and MP-M-specific CD4⁺
112 TCL, we sorted live CD3⁺CD4⁺ T cells from each TCL (to avoid any contamination with
113 remaining feeder cells or CD8⁺ T cells) and used single cell RNAseq to understand more fully
114 the nature (and heterogeneity) of these TCLs.

115 Analyses of the single-cell mRNA data of between all the SARS-CoV-2 spike protein-
116 reactive CD4⁺ TCLs with the SARS-Cov-2 membrane protein-reactive CD4⁺ TCLs revealed a
117 clear distinction and a unique transcriptional signature for each of the M- and S-reactive TCLs
118 (Figure 3A-B). Differential gene expression analysis of the 20 topmost significant genes showed
119 that in contrast to CD4⁺ TCLs reactive to SARS-CoV-2 M protein, the S protein specific-CD4⁺
120 T cell lines expressed higher levels of CCL1, GNL1 (Granulysin), TNFRSF18 (GITR),
121 NFKBIA, IGLC3, among other genes (Figure 3E), suggesting an effector cytotoxic role for MP-
122 S-reactive CD4⁺ T cells. In marked contrast, CD4⁺ TCLs reactive to SARS-CoV-2 M protein
123 showed increased expression of GZMA (Granzyme A) and the EEF (eukaryotic elongation

124 factors) gene family, including EEF1A1, EEF1B2, EEF1G, EEF2, EIF3E. Most striking,
125 however, the MP-M reactive CD4⁺ T cell lines revealed a marked and significant overall
126 suppressed expression of interferon-inducible genes, including ISG15 (interferon-stimulated
127 gene 15) and IFITM1 (Interferon Induced Transmembrane Protein 1) (Figure 3F).

128 Interestingly, comparative analyses between the single-cell transcriptional profiling of
129 SARS-CoV-2 S and M proteins-specific CD4⁺ TCLs and those from CMV-specific-CD4⁺ TCLs
130 (Figure S1A), demonstrated that S-specific responses are virtually indistinguishable from those
131 responses induced by CMV (Figure S1B). Not surprisingly then, the SARS-CoV-2 M-specific
132 responses continue to demonstrate a profoundly marked suppression of the interferon signaling
133 pathway in comparison to CMV-specific CD4⁺ TCLs (Figure S1C), a suppression characterized
134 by a significant downregulation of BAX, IFI6, IFI35, IFIT3, IRF9, ISG15, MX1, OAS1 and
135 STAT1 (Figure S1D).

136

137 **SARS-CoV-2 protein M-specific CD4⁺ T cells reveals marked downregulation of interferon** 138 **pathway signaling**

139 We next performed Ingenuity Pathway Analysis (IPA[®]) on the significantly differentially
140 expressed genes in MP-M- compared with MP-S-reactive CD4⁺ TCLs. Interestingly, the IPA
141 analysis showed that the canonical pathway signaling with immunological relevance most
142 affected in the MP-M-specific CD4⁺ TCLs was the interferon signaling pathway ($p=1.59^{-10}$) and
143 negative z-score (-2.333) (Figure 4A) indicating an extensive and comprehensive suppression of
144 the genes related to types I, II, and III interferon signaling induced by SARS-CoV-2 M protein
145 (Figure 4B), including ISG15, IFITM1, IFI6, MX1, STAT1, OAS1, IFI35, IFIT3 and IRF7
146 (Figure 4C-D). In addition, upstream analysis also revealed that the MP-M-reactive CD4⁺ TCLs

147 show a marked inhibition of the IFNA2- (interferon alpha 2, z-score= -3.561, p=5.7⁻¹⁸), IFNB1-
148 (interferon beta, z-score= -3.312, p=9.6⁻¹⁴), IFNG- (interferon gamma, z-score= -2.899, p=7.2⁻¹⁷)
149 and IFNL1- (interferon lambda, z-score= -3.646, p=8.3⁻¹⁷) associated pathways.

150

151 **The molecular signature of SARS-CoV-2 M protein-reactive CD4⁺ TCLs associates with**
152 **the transcriptional profile seen in severe Covid-19**

153 After characterizing the transcriptional profile of SARS-Cov-2 specific CD4⁺ TCLs, the
154 next step was to use the molecular signature of M protein-reactive T cells to understand how they
155 relate to other diseases and functions through the IPA™ ontology. The transcriptome of SARS-
156 Cov-2 M protein-reactive CD4⁺ TCLs revealed pathways associated with a diverse list of
157 inflammatory diseases and functions, including the top 3: viral infection (107 overlapping
158 molecules, p=7.0⁻³³), systemic autoimmune syndrome (86 overlapping molecules, p=1.3⁻²⁸), and
159 most strikingly, Severe COVID-19 (31 overlapping molecules, p=6.8⁻²⁸) (Figure 5B). The 31
160 severe COVID-19-associated genes that overlapped with the differentially expressed genes in the
161 SARS-Cov-2 M protein-reactive CD4⁺ TCLs were identified and plotted based on their
162 expression level (Figure 5C). Interestingly, the upregulation of the inflammatory genes FOS,
163 JUNB, the downregulation of the interferon-induced genes, including ISG15, IFI6, IFI44, IFIT3,
164 IFI44L, and suppression of the interferon regulatory factors, including (IRF7) driven by M
165 protein were implicated as the key players for this association, suggesting that the molecular
166 signature of SARS-CoV-2 M protein-reactive CD4⁺ TCLs is characterized by suppression of the
167 same interferon pathways seen in the transcriptional profile of severe Covid-19.

168

169

170 Discussion

171 There is a critical need for elucidating the nature of antigen specificity and function of the
172 memory T cell responses to SARS-CoV-2. Understanding the contribution of adaptive immunity
173 to a protective or pathogenic role in SARS-CoV-2 infection may lead the way to a fundamental
174 knowledge that can possibly be used therapeutically in COVID-19 patients or as vaccine targets.

175 SARS-CoV-2 infected-patients develop specific antibodies, CD4⁺ T cells, and CD8⁺ T
176 cells in response to the infection [3, 6, 8, 9] , although, CD4⁺ T cells had the strongest association
177 with diminished COVID-19 disease severity compared with the other two arms (B cells, CD8⁺ T
178 cells) of the adaptive immunity [6]. Strikingly, the absence of SARS-CoV-2-specific CD4⁺ T
179 cells was associated with severe or fatal COVID-19 [9]. Data from other another coronavirus
180 (SARS-CoV-1) reported that SARS-CoV-1 spike protein was responsible for nearly two-thirds
181 of the CD4⁺ T cell reactivity with limited reactivity for M and N proteins [15] . It seems,
182 however, that the pattern of antigen predominance of SARS-Cov-2-driven immune responses is
183 different from SARS-CoV-1 in that there is strong reactivity of CD4⁺ T cells to viral S, M and N
184 structural proteins, as well as, to other non-structural proteins and open reading frames, including
185 ORF3 and NSP3 [3, 10, 16-18].

186 The relationship between antigen-specific CD4⁺ T cell responses and COVID-19 severity
187 remains unclear. First it has been demonstrated that mild COVID-19 patients, who typically
188 recover without special treatment, showed broad SARS-CoV-2-specific CD4⁺ T cell responses to
189 S and N proteins, responses that were highly correlated with specific antibody titers [18].
190 However, T cell responses were imbalanced in critical ICU patients with a functionally impaired
191 CD4⁺ T cell response showing reduced production of IFN- γ and TNF- α [19].

192 Indeed, an inflammatory cytokine and chemokine signature (elevated CXCL10, IL-6, and
193 IL-8) accompanied by ineffective interferon responses has been strongly associated with failure
194 to control a primary SARS-CoV-2 infection and with a higher risk of fatal COVID-19 [20-22].
195 Moreover, impaired, and delayed type I and type III IFN responses have been associated with a
196 higher risk of severe COVID-19 [23]. Interferons (IFNs), including type I (IFN- α and IFN- β) and
197 type III (IFN- λ) are central to both combating virus infection and modulating the antiviral
198 immune response [24, 25]. While type I IFNs are widely expressed and can result in immune-
199 mediated pathology during viral infections, type III IFN (IFN- λ) responses are primarily
200 restricted to mucosal surfaces and are associated with protection to viruses without driving
201 damaging proinflammatory responses [26].

202 Interestingly, coronaviruses develop efficient immune evasion mechanisms by
203 manipulating immune responses and by interfering with the IFN-related pathways [27]. Indeed,
204 several structural (M and N) and non-structural (NSP1 and NSP3) proteins from SARS-CoV and
205 MERS-CoV can act as interferon antagonists [28]. Notwithstanding, SARS-CoV-2 M protein has
206 also been implicated to antagonize type I and III IFN production by affecting the formation of
207 the RIG-I/MDA-5–MAVS–TRAF3–TBK1 signalosome that has been shown to attenuate
208 antiviral immunity and enhance viral replication [11]. Here, using single-cell transcriptomes of
209 human CD4⁺ T cells reactive to either S protein or M protein, we have shown that SARS-CoV-2
210 M protein-reactive CD4⁺ T cells in comparison with S protein, expressed higher levels of the
211 inflammatory genes FOS, JUNB and lower levels of ISGs, including ISG15, IFI6, IFI35, IFI44,
212 IFIT3, IFITM1, STAT1, OAS1, and interferon regulatory factors, including (IRF7). Viral
213 recognition elicits IFN production, which in turn triggers the transcription of IFN-stimulated
214 genes (ISGs), which engage in various antiviral functions. ISGs have a central role to regulate

215 the type I interferon [29]. Among these ISGs, ubiquitin-like protein ISG15 is one of the most
216 strongly and rapidly induced, and recent work has shown that it can directly inhibit viral
217 replication and modulate host immunity [30-32]. Similarly, we also observed that the molecular
218 signature of SARS-CoV-2 M protein-reactive CD4⁺ T cells, is characterized by suppression in the
219 interferon pathways, genetically associates with the transcriptional profile of severe Covid-19.

220 Notably, through single cell RNAseq analysis of T-cell dysregulation in severe COVID-
221 19 it has been demonstrated that CD4⁺ T cells from severe COVID-19 patients expressed higher
222 levels of a set of inflammatory genes that include FOS, FOSB, JUN and others, gene expression
223 [33] not dissimilar to those found in our M-specific T cells derived from SARS-CoV-2 unexposed
224 individuals. In parallel, this same study showed that CD4⁺ T cells from patients with severe
225 COVID-19 showed decreased expression of interferon-induced genes including IFIT1, IFIT2,
226 IFIT3, and IFITM1 and those downstream from interferon signaling [33], again striking similar
227 to the molecular signature seen in the M protein-reactive CD4⁺ T cells in this present study.
228 Finally, the mechanisms by how the peptide megapools of M and S proteins underlies different
229 responses of naïve CD4⁺ T cells remains unclear. Future studies are needed to elucidate if the M-
230 driven dysregulation of interferon signaling pathway in the adaptive immunity resemble to the
231 mechanisms already described including the interaction with pattern recognition receptors
232 (PRRs)-downstream molecules of innate cells, or if it is induced by the interaction of the class II
233 MHC-peptide complex with the restricted TCR repertoire of naïve T cells.

234 In conclusion, although it has been poorly understood how CD4⁺ T cell dysregulation can
235 contribute to the immunopathogenesis of severe COVID-19, our study suggests a potential link
236 between the antigen specificity of the reactive CD4⁺ T cells to SARS-CoV-2 with the
237 development of a functional and efficient adaptive immune response. The discordant response to

238 S compared to M proteins suggest that the balance between the T cells of different specificities
239 may alter immune evasion mechanisms that may, in turn, drive disease severity. Therefore, one
240 could envision therapeutic approaches that also targets the SARS-CoV-2 M protein may also be
241 important for amelioration of severity of COVID-19.

242

243 **Methods**

244 **CMV-specific or SARS-CoV-2 spike or membrane protein-specific CD4⁺ T cell lines**

245 **generation from unexposed individuals**

246 The protocol for generating an antigen (CMV, SARS-CoV-2-Spike, SARS-CoV-2 Membrane)-
247 specific CD4⁺ T cell line were adapted from previous studies [34, 35]. Briefly, naïve CD4⁺ T
248 cells, as well as monocytes were purified from cryopreserved PBMCs of 6 healthy donor
249 individuals unexposed to SARS-CoV-2 (obtained prior to 2019), using magnetic cell sorting
250 (MACS Miltenyi Biotec, USA). Purified monocytes were differentiated into dendritic cells
251 (DCs) by a 6 day-culture in complete R10 media [RPMI 1640 medium (Gibco) supplemented
252 with 10% heat-inactivated AB serum (Pan Biotech), 1% nonessential amino acids, 1% HEPES
253 1M, 1 mM sodium pyruvate, 2 mM fresh l-glutamine, 100 µg/ml streptomycin, 100 units/ml
254 penicillin (all from Life Technologies, USA)] at 37°C, 5% CO₂. 10µL of GM-CSF (1mg/mL)
255 and 10µL of IL-4 (1mg/mL) were added at days 1, 3 and 5. At day 6, immature DCs were
256 harvest, washed and incubated overnight with 10µL of IFN-γ (1,000 units/mL) and LPS
257 (100ng/mL) for maturation. At day 7, 1x10⁵ matured DCs were separately seeded in 24 wells
258 plate, and then loaded for 2-4 hours with 1µg/peptide of SARS-CoV-2 peptide megapools (MPs)
259 covering either the entire sequence of SARS-CoV-2 spike protein (MP-S), consisted by a 15-mer
260 peptides overlapping by 10-residues (246 peptides) [10] or covering the complete sequence of

261 SARS-CoV-2 membrane protein (MP-M), consisting of 15-mer sequences with 11 amino acids
262 overlap (PepTivator® SARS-CoV-2 Prot_M, Miltenyi Biotec, USA) and 1µg/peptide of CMV
263 peptide megapools (~500 peptides). On the top of the either MP-S, MP-M or CMV pulsed-DCs,
264 1x10⁶ naïve CD4⁺ T cells (1:10 ratio) were added and incubated for 12 days in complete R10
265 media. On days 2, 5 and 8, 60units of human rIL-2 (Cetus, USA) were added at each well. At
266 day 12, cells in culture were washed, counted, and fed (1:1 ratio) with irradiated (40GY)
267 autologous PBMCs (feeder cells) in the presence of either 1µg/peptide of MP-S or MP-M for
268 another 12-day round culture in the same conditions, including the IL-2 stimulation. After three
269 12-day rounds of peptide pool stimulation/expansion *in vitro*, we generated a total of 18, 6 MP-
270 S-specific, 6 MP-M-specific and 6 CMV-specific CD4⁺ T cells, which were profiled for antigen-
271 specificity and reactivity using multiparameter flow cytometry.

272

273 **Responsiveness and specificity of SARS-CoV-2-specific CD4⁺ T cell line by flow cytometry**

274 The generation of the different SARS-Cov-2-specific CD4⁺ T cell lines and their specificity and
275 reactivity were confirmed by an immunophenotypic and functional assay where the cell lines
276 were stimulated overnight in 5% CO₂ at 37°C with their irradiated autologous feeder cells in the
277 absence (media) or in the presence of their respective antigens (1µg/peptide of MP-S or
278 1µg/peptide of MP-M). Both CD4⁺ T cells were also stimulated with 1µg/peptide of a peptide
279 megapool that cover the CD4-predicted epitopes sequences for Cytomegalovirus (MP-CMV) and
280 PMA/ionomycin (Sigma-Aldrich) (0.5/0.05 µg/ml). The cells were then stained for viability
281 (Live/Dead fixable blue (UV450), Molecular Probes), and then incubated with anti-CD3
282 (BV421), anti-CD4 (PerCP-Cy5.5) for 30 min in the dark at room temperature. The cells were
283 next washed twice with FACS buffer, then fixed and permeabilized using a Fix/Perm buffer kit

284 (BioLegend) for 30 min at 4°C. The cells were washed twice with Perm buffer (BioLegend) and
285 resuspended with the intracellular antibody pool containing anti-CD69 (FITC), anti-CD154
286 (APC), anti-TNF- α (Alexa Fluor 700) and anti-IFN- γ (BUV737) (Supplemental Table I) for 30
287 min at 4°C. Finally, the cells were washed twice with Perm buffer and then acquired using the
288 BD LSRFortessa flow cytometer (BD Biosciences) and FACSDiva software (BD Biosciences)
289 for acquisition. All analyses were performed using FlowJo v10.5.3.

290

291 **DNA purification for whole exome sequencing**

292 Genomic DNA purified (Promega) from 30×10^6 PBMCs of the 6 healthy donor individuals
293 unexposed to SARS-CoV-2 (the donors we used to generate the SARS-CoV-2-specific CD4⁺
294 TCLs) was sent for whole exome sequencing and HLA-typing at Psomagen, Inc.

295

296 **Sample preparation and single-cell RNA-seq libraries for next generation sequencing**

297 In summary, 1×10^5 live CD3⁺CD4⁺ T cells were sorted from the 6 MP-S, MP-M and
298 CMV-specific CD4⁺ T cell lines cultures using a BD FACSAria Cell Sorter (BD Biosciences). 1
299 $\times 10^4$ cells of each CD4⁺ TCLs were pooled together for both conditions separately.

300 Approximately 6×10^3 multiplexed cells (a thousand cells per donor for each cell line) were
301 loaded in three lanes of the Chromium Next GEM Chip G (10x Genomics) respectively, one for
302 MP-S, another for MP-M and another for CMV-specific-CD4⁺ TCLs, resulting in three 10x
303 Genomics Single Cell Chromium 3' mRNA libraries, made in accordance with Chromium Single
304 Cell 3' Reagent Kits User Guide (v3.1).

305

306 **Single cell RNA-Seq analysis**

307 Two 10x Genomics Single Cell Chromium 3' mRNA libraries were made and sequenced as part
308 of one Illumina NextSeq run. Each sample had a sequencing yield of greater than 68 million
309 reads. The sequencing run was setup with 150 cycles + 150 cycles symmetric run. Initial
310 processing of the two samples included removal of the cells with extremely low number of UMI
311 counts using Cellranger v4.0.0 using default parameters except for the forced cell counts which
312 were 1,979 for S and 1,461 for M. Demuxlet [36] was used with matching exome SNP data to
313 call cell genotypes and multiplet annotations. The remainder of the single cell RNA-Seq
314 (scRNA) analysis was performed with Seurat v3.2.2 [37]. SingleR [38] utilizing data available
315 from the Novershtern Hematopoietic database [39] was used for cell type identification. For
316 sample S, after filtering for less than 500 and greater than 6000 detected genes, higher than 15%
317 mitochondrial gene expression, anything other than CD4⁺ annotation by SingleR, and multiplets
318 called by demuxlet, retained 713 of the 1,979 cells. For Sample M, after filtering for less than
319 200 and greater than 5000 detected genes, higher than 15% mitochondrial gene expression,
320 anything other than CD4⁺ annotation by SingleR, and multiplets called by demuxlet, retained
321 1,132 of the 1,461 cells. Samples S and M were merged using Seurat and standard scRNA
322 analysis was done using 20 principal components (PCs) to visualize the UMAP diagrams. Initial
323 clustering with UMAP identified 2 cell clusters separating the S and M samples. Differential
324 expression analysis was performed to identify cluster-specific markers and to compare the S and
325 M cell populations using MAST [40], or "Model-based Analysis of Single-cell Transcriptomics",
326 whereas the cluster-specific canonical pathway enrichment profiles were generated using
327 Ingenuity Pathway Analysis (IPA, Qiagen, Redwood City, CA, USA).

328

329 **Study approval**

330 This study (NCT00001230) was approved by the National Institute of Allergy and Infectious
331 Diseases (NIAID) Institutional Review Board. Written informed consent was obtained from all
332 participants.

333
334 **Author contributions:** Conceptualization: PHGG, GS, AS, DW and TBN. Methodology:
335 PHGG, GS, AS, DW, PS, JL. Investigation: PHGG, GS, PS, JL. Visualization: PHGG, GS, PS.
336 Funding acquisition: PHGG, TBN. Project administration: PHGG, TBN. Supervision: PHGG,
337 TBN. Writing – original draft: PHGG. Writing – review & editing: PHGG, GS, AS, DW, PS, JL,
338 TBN.

339

340 **Competing interests**

341 A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape,
342 CellCarta, Oxford Immunotec, and Avalia Immunotherapies. LJI has filed for patent protection
343 for various aspects of T cell epitope and vaccine design work.

344

345 **Acknowledgments**

346 This study was supported by the Division of Intramural Research, NIAID, NIH and partly by
347 NIH contract Nr. 75N9301900065 (D.W., A.S.).

348

349 **References**

350 1. Hu, B., et al., *Characteristics of SARS-CoV-2 and COVID-19*. Nat Rev Microbiol, 2021.
351 **19(3):** p. 141-154.


- 352 2. Raoult, D., et al., *Coronavirus infections: Epidemiological, clinical and immunological*
353 *features and hypotheses*. Cell Stress, 2020. **4**(4): p. 66-75.
- 354 3. Le Bert, N., et al., *SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS,*
355 *and uninfected controls*. Nature, 2020. **584**(7821): p. 457-462.
- 356 4. Tan, A.T., et al., *Early induction of functional SARS-CoV-2-specific T cells associates with*
357 *rapid viral clearance and mild disease in COVID-19 patients*. Cell Rep, 2021. **34**(6): p.
358 108728.
- 359 5. Liao, M., et al., *Single-cell landscape of bronchoalveolar immune cells in patients with*
360 *COVID-19*. Nat Med, 2020. **26**(6): p. 842-844.
- 361 6. Rydzynski Moderbacher, C., et al., *Antigen-Specific Adaptive Immunity to SARS-CoV-2 in*
362 *Acute COVID-19 and Associations with Age and Disease Severity*. Cell, 2020. **183**(4): p.
363 996-1012 e19.
- 364 7. Dan, J.M., et al., *Immunological memory to SARS-CoV-2 assessed for up to eight months*
365 *after infection*. bioRxiv, 2020.
- 366 8. Ni, L., et al., *Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in*
367 *COVID-19 Convalescent Individuals*. Immunity, 2020. **52**(6): p. 971-977 e3.
- 368 9. Sette, A. and S. Crotty, *Adaptive immunity to SARS-CoV-2 and COVID-19*. Cell, 2021.
369 **184**(4): p. 861-880.
- 370 10. Grifoni, A., et al., *Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans*
371 *with COVID-19 Disease and Unexposed Individuals*. Cell, 2020. **181**(7): p. 1489-1501 e15.
- 372 11. Zheng, Y., et al., *Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)*
373 *membrane (M) protein inhibits type I and III interferon production by targeting RIG-*
374 *I/MDA-5 signaling*. Signal Transduct Target Ther, 2020. **5**(1): p. 299.

- 375 12. Siu, K.L., et al., *Severe acute respiratory syndrome coronavirus M protein inhibits type I*
376 *interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon*
377 *complex*. J Biol Chem, 2009. **284**(24): p. 16202-16209.
- 378 13. Xia, H., et al., *Evasion of Type I Interferon by SARS-CoV-2*. Cell Rep, 2020. **33**(1): p.
379 108234.
- 380 14. Fu, Y.Z., et al., *SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated*
381 *innate antiviral response*. Cell Mol Immunol, 2021. **18**(3): p. 613-620.
- 382 15. Li, C.K., et al., *T cell responses to whole SARS coronavirus in humans*. J Immunol, 2008.
383 **181**(8): p. 5490-500.
- 384 16. Nelde, A., et al., *SARS-CoV-2-derived peptides define heterologous and COVID-19-*
385 *induced T cell recognition*. Nat Immunol, 2021. **22**(1): p. 74-85.
- 386 17. Peng, Y., et al., *Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-*
387 *CoV-2 in UK convalescent individuals following COVID-19*. Nat Immunol, 2020. **21**(11):
388 p. 1336-1345.
- 389 18. Oja, A.E., et al., *Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not*
390 *mild COVID-19 patients*. Eur J Immunol, 2020. **50**(12): p. 1998-2012.
- 391 19. Zheng, H.Y., et al., *Elevated exhaustion levels and reduced functional diversity of T cells*
392 *in peripheral blood may predict severe progression in COVID-19 patients*. Cell Mol
393 Immunol, 2020. **17**(5): p. 541-543.
- 394 20. Aid, M., et al., *Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus*
395 *Macaques*. Cell, 2020. **183**(5): p. 1354-1366 e13.
- 396 21. Kuri-Cervantes, L., et al., *Comprehensive mapping of immune perturbations associated*
397 *with severe COVID-19*. Sci Immunol, 2020. **5**(49).

- 398 22. Del Valle, D.M., et al., *An inflammatory cytokine signature predicts COVID-19 severity*
399 *and survival*. Nat Med, 2020. **26**(10): p. 1636-1643.
- 400 23. Kim, Y.M. and E.C. Shin, *Type I and III interferon responses in SARS-CoV-2 infection*.
401 Exp Mol Med, 2021. **53**(5): p. 750-760.
- 402 24. Muller, U., et al., *Functional role of type I and type II interferons in antiviral defense*.
403 Science, 1994. **264**(5167): p. 1918-21.
- 404 25. Lee, A.J. and A.A. Ashkar, *The Dual Nature of Type I and Type II Interferons*. Front
405 Immunol, 2018. **9**: p. 2061.
- 406 26. Hadjadj, J., et al., *Impaired type I interferon activity and inflammatory responses in severe*
407 *COVID-19 patients*. Science, 2020. **369**(6504): p. 718-724.
- 408 27. Taefehshokr, N., et al., *Covid-19: Perspectives on Innate Immune Evasion*. Front Immunol,
409 2020. **11**: p. 580641.
- 410 28. Fung, T.S. and D.X. Liu, *Human Coronavirus: Host-Pathogen Interaction*. Annu Rev
411 Microbiol, 2019. **73**: p. 529-557.
- 412 29. Schneider, W.M., M.D. Chevillotte, and C.M. Rice, *Interferon-stimulated genes: a*
413 *complex web of host defenses*. Annu Rev Immunol, 2014. **32**: p. 513-45.
- 414 30. Der, S.D., et al., *Identification of genes differentially regulated by interferon alpha, beta,*
415 *or gamma using oligonucleotide arrays*. Proc Natl Acad Sci U S A, 1998. **95**(26): p. 15623-
416 8.
- 417 31. Loeb, K.R. and A.L. Haas, *The interferon-inducible 15-kDa ubiquitin homolog conjugates*
418 *to intracellular proteins*. J Biol Chem, 1992. **267**(11): p. 7806-13.
- 419 32. Perng, Y.C. and D.J. Lenschow, *ISG15 in antiviral immunity and beyond*. Nat Rev
420 Microbiol, 2018. **16**(7): p. 423-439.

- 421 33. Kalfaoglu, B., et al., *T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection*
422 *Revealed by Single-Cell Analysis*. Front Immunol, 2020. **11**: p. 589380.
- 423 34. Nutman, T.B., et al., *Parasite antigen-specific human T cell lines and clones. Major*
424 *histocompatibility complex restriction and B cell helper function*. J Clin Invest, 1984.
425 **73**(6): p. 1754-62.
- 426 35. Kahlert, H., *Production of T-cell lines*. Methods Mol Med, 2008. **138**: p. 31-41.
- 427 36. Kang, H.M., et al., *Multiplexed droplet single-cell RNA-sequencing using natural genetic*
428 *variation*. Nat Biotechnol, 2018. **36**(1): p. 89-94.
- 429 37. Stuart, T., et al., *Comprehensive Integration of Single-Cell Data*. Cell, 2019. **177**(7): p.
430 1888-1902 e21.
- 431 38. Aran, D., et al., *Reference-based analysis of lung single-cell sequencing reveals a*
432 *transitional profibrotic macrophage*. Nat Immunol, 2019. **20**(2): p. 163-172.
- 433 39. Novershtern, N., et al., *Densely interconnected transcriptional circuits control cell states*
434 *in human hematopoiesis*. Cell, 2011. **144**(2): p. 296-309.
- 435 40. Finak, G., et al., *MAST: a flexible statistical framework for assessing transcriptional*
436 *changes and characterizing heterogeneity in single-cell RNA sequencing data*. Genome
437 Biol, 2015. **16**: p. 278.

438




439


440 **Figure 1:** SARS-Cov-2 antigen-specific CD4⁺ T-cell line generation from healthy donor PBMC.

441 Panel A demonstrates the methodology used for generation of the various TCLs beginning with
 442 healthy donor naive T-cells and driven by SARS-Cov-2 structural spike (S) and membrane (M)
 443 protein-based peptide megapools. Panel B shows a representative flow cytometric analysis of the
 444 of MP-S-specific CD4⁺ TCLs expressing CD69⁺CD154⁺ in comparison with their respective
 445 naïve CD4⁺ T cells. Moreover, upon stimulation with their respective MPs, the vast majority of
 446 CD69⁺CD154⁺ MP-S specific-CD4⁺ T cell lines were either IFN-γ⁺ or TNF-α⁺.

447




448
 449 **Figure 2:** Profiling of SARS-CoV-2 spike (S) and membrane (M) proteins-specific CD4⁺ T cell
 450 line for antigen specificity. SARS-Cov-2 spike protein-specific CD4⁺ TCLs from 6 different
 451 donors were cultured *in vitro* in the absence (media) or in the presence of different stimulation
 452 conditions including: either SARS-Cov-2 S protein peptide pool (1 μg/peptide) or M protein
 453 peptide pool (1 μg/peptide); CMV peptide pool (1μg/peptide); and PMA/ionomycin
 454 (0.5/0.05pg/mL). Panels A and C show a representative flow cytometric analysis of the of both
 455 MP-S or MP-M-specific CD4⁺ TCLs expressing CD69⁺CD154⁺ and the subsequent antigen-
 456 specific cells expressing either IFN-γ⁺ or TNF-α⁺ after the different stimulation conditions.
 457 Panels B and D reveal the specificity and the reactivity of the six MP-S specific CD4⁺ TCLs (B)
 458 or the six MP-M specific CD4⁺ TCLs (D) demonstrating the frequency of CD69⁺CD154⁺ TCLs
 459 producing either IFN-γ or TNF-α upon stimulation, in comparison with the unstimulated
 460 condition. Each plot represents the CD4⁺ TCLs from each donor (n=6) which the circles
 461 represent the unstimulated cells and the squares are the respective stimulated conditions. All
 462 differences by Wilcoxon matched-pairs test with P < 0.05 are indicated in the graph.
 463




464
 465 **Figure 3:** Single-cell transcriptional profiling of SARS-CoV-2 spike (S) and membrane (M)
 466 protein-specific CD4⁺ T cell lines (A). Transcriptional signature of both MP-S and MP-M
 467 specific-CD4⁺ T cell lines deconvoluted by patient (colored based from P1-P6) is displayed by
 468 manifold approximation and projection (UMAP) (B-C). (D) Heatmap showing expression of the
 469 most significantly 50 enriched transcripts in each cluster. (E-F) Plot shows average expression
 470 and percent expression of selected marker transcripts in each cluster.

471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484



485
 486 **Figure 4.** SARS-CoV-2 membrane (M) protein downregulates types I, II, III interferon pathway
 487 signaling in CD4⁺ T cell lines generated from unexposed individuals. Canonical signaling
 488 pathways of immunological relevance affected in M protein-specific TCLs (A) indicating a
 489 marked suppression interferon signaling pathway and others, including Th1 pathway. (B) Map of
 490 the interferon signaling pathway indicating the 9 downstream molecules that were associated
 491 with the suppression of interferon, where in green are the genes affected negatively or in red the
 492 genes upregulated by SARS-CoV-2 M protein. Feature graph (C) and the violin plot graph (D)
 493 showing the average expression and the percent expression of the interferon signaling pathway
 494 genes in the respective S-protein-specific CD4⁺ T cell lines and M-protein-specific CD4⁺ T cell
 495 lines.
 496



497

498 **Figure 5.** IPA analysis demonstrating an overview summary of the major biological events in the
 499 transcriptome of SARS-CoV-2 M protein-reactive CD4⁺ TCLs (A) and The Disease or Function
 500 View highlighting how the SARS-Cov-2 specific-CD4⁺ TCLs relate to other diseases and
 501 functions through the ingenuity ontology (B). Severe COVID-19 associated genes that overlap
 502 with the marked differentially expressed genes in the SARS-Cov-2 M protein-reactive CD4⁺
 503 TCLs (C).